Posted at 2:48 p.m., Monday, November 26, 2007
Hawaii Biotech receives $2.1M for vaccine testing
Advertiser Staff
'Aiea-based Hawaii Biotech recently received $2.1 million in investments which will be used to finance clinical trials of west Nile vaccine and development of the company's Dengue and seasonal flu programs.Investors, who received a new series of preferred stock, include Hawai'i investors and Chopin Opus One. Chopin Opus is a major shareholder in Brisbane, Australia-based Avantogen Ltd., which owns 48 percent of Hawaii Biotech.
Hawaii Biotech is still awaiting approval for an application filed with the U.S. Food and Drug Administration to conduct human clinical trials for a West Nile virus vaccine.
